Arsanis, Inc. (ASNS) Declines to All-Time Low at $3.74

June 29, 2018 - By Margaret Staats

Arsanis, Inc. (NASDAQ:ASNS) reached all time low on Jun, 29 with $3.48 PT or 7.00 % below the last $3.74 share price. published the all time low. The company has $53.46M market cap. At $3.48 PT, the company’s valuation could be $3.74M less.

Ticker’s shares touched $3.74 during the last trading session after 6.50% change.Arsanis, Inc. has 289,279 shares volume, 429.35% up from normal. ASNS is and has moved 0.00% since June 29, 2017. ASNS underperformed the S&P500 by 12.57%.

Arsanis, Inc. (NASDAQ:ASNS) is awaited to announce earnings on August, 9., as reported by RTT. Analysts at Wall Street see Arsanis, Inc.’s 6.76 % negative EPS growth compared to $-0.74 earnings per share for previous quarter.

For more Arsanis, Inc. (NASDAQ:ASNS) news announced briefly go to:,,, or The titles are as follows: “Pre-Open Movers 06/28: (DRRX) (ZSAN) (CAVM) Higher; (ASNS) (PIR) (WBA) Lower (more…)” announced on June 28, 2018, “Mid-Morning Market Update: Markets Edge Lower; Walgreens Beats Q3 Views” on June 28, 2018, “24 Stocks Moving In Friday’s Pre-Market Session” with a publish date: June 29, 2018, “Mid-Afternoon Market Update: Dow Rises Over 100 Points; Progress Software Shares Spike Higher” and the last “48 Biggest Movers From Yesterday” with publication date: June 29, 2018.

Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody immunotherapies to address serious infectious diseases.The company has $53.46 million market cap. The Company’s lead product candidate is ASN100, a first-in-class mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia.Last it reported negative earnings. The company's preclinical pipeline comprises mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.

Arsanis, Inc. (NASDAQ:ASNS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.